NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (CAMMA 1)

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion using a modified weekly schedule.

Sponsor:

Genentech, Inc.

Collaborator:

Hoffmann-La Roche

Multiple locations

International Study

---

ClinicalTrials.gov Identifier: NCT04910568

Official Title: An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patients With Relapsed or Refractory Multiple Myeloma